ICCC
Price
$6.80
Change
+$0.05 (+0.74%)
Updated
Jun 30, 10:32 AM (EDT)
Capitalization
61M
38 days until earnings call
RLYB
Price
$0.33
Change
-$0.00 (-0.00%)
Updated
Jun 30, 02:36 PM (EDT)
Capitalization
13.84M
37 days until earnings call
Interact to see
Advertisement

ICCC vs RLYB

Header iconICCC vs RLYB Comparison
Open Charts ICCC vs RLYBBanner chart's image
ImmuCell
Price$6.80
Change+$0.05 (+0.74%)
Volume$455
Capitalization61M
Rallybio
Price$0.33
Change-$0.00 (-0.00%)
Volume$4.55K
Capitalization13.84M
ICCC vs RLYB Comparison Chart in %
Loading...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLYB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ICCC vs. RLYB commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICCC is a Hold and RLYB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ICCC: $6.75 vs. RLYB: $0.33)
Brand notoriety: ICCC and RLYB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ICCC: 71% vs. RLYB: 69%
Market capitalization -- ICCC: $61M vs. RLYB: $13.84M
ICCC [@Biotechnology] is valued at $61M. RLYB’s [@Biotechnology] market capitalization is $13.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICCC’s FA Score shows that 0 FA rating(s) are green whileRLYB’s FA Score has 1 green FA rating(s).

  • ICCC’s FA Score: 0 green, 5 red.
  • RLYB’s FA Score: 1 green, 4 red.
According to our system of comparison, both ICCC and RLYB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICCC’s TA Score shows that 3 TA indicator(s) are bullish while RLYB’s TA Score has 6 bullish TA indicator(s).

  • ICCC’s TA Score: 3 bullish, 5 bearish.
  • RLYB’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, RLYB is a better buy in the short-term than ICCC.

Price Growth

ICCC (@Biotechnology) experienced а -11.18% price change this week, while RLYB (@Biotechnology) price change was +8.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.95%, and the average quarterly price growth was +6.81%.

Reported Earning Dates

ICCC is expected to report earnings on Aug 07, 2025.

RLYB is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ICCC($61M) has a higher market cap than RLYB($13.8M). ICCC YTD gains are higher at: 31.068 vs. RLYB (-65.354). ICCC has higher annual earnings (EBITDA): 2.94M vs. RLYB (-50.26M). RLYB has more cash in the bank: 54.5M vs. ICCC (4.6M). RLYB has less debt than ICCC: RLYB (116K) vs ICCC (14.7M). ICCC has higher revenues than RLYB: ICCC (27.3M) vs RLYB (848K).
ICCCRLYBICCC / RLYB
Capitalization61M13.8M442%
EBITDA2.94M-50.26M-6%
Gain YTD31.068-65.354-48%
P/E RatioN/AN/A-
Revenue27.3M848K3,219%
Total Cash4.6M54.5M8%
Total Debt14.7M116K12,672%
FUNDAMENTALS RATINGS
ICCC: Fundamental Ratings
ICCC
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
75
SMR RATING
1..100
90
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ICCCRLYB
RSI
ODDS (%)
Bearish Trend 4 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 18 days ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
76%
Bearish Trend 13 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RLYB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UNF186.320.36
+0.19%
Unifirst Corp
WRB72.29-0.05
-0.07%
WR Berkley Corp
ISRL12.58-0.01
-0.08%
Israel Acquisitions Corp
CLW27.93-0.05
-0.18%
Clearwater Paper Corp
NCL0.17-0.01
-3.78%
Northann Corp

ICCC and

Correlation & Price change

A.I.dvisor tells us that ICCC and MYNDF have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICCC and MYNDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
-0.59%
MYNDF - ICCC
24%
Poorly correlated
N/A
NERV - ICCC
23%
Poorly correlated
-2.22%
TRAW - ICCC
23%
Poorly correlated
N/A
RLYB - ICCC
23%
Poorly correlated
-8.25%
MNOV - ICCC
22%
Poorly correlated
+2.31%
More

RLYB and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLYB has been loosely correlated with PRME. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RLYB jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLYB
1D Price
Change %
RLYB100%
-8.25%
PRME - RLYB
42%
Loosely correlated
-8.68%
ATXS - RLYB
42%
Loosely correlated
N/A
GBIO - RLYB
38%
Loosely correlated
-15.40%
SLNO - RLYB
36%
Loosely correlated
-0.92%
LYEL - RLYB
36%
Loosely correlated
-1.97%
More